123 related articles for article (PubMed ID: 1657373)
1. Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin.
Isonishi S; Hom DK; Thiebaut FB; Mann SC; Andrews PA; Basu A; Lazo JS; Eastman A; Howell SB
Cancer Res; 1991 Nov; 51(21):5903-9. PubMed ID: 1657373
[TBL] [Abstract][Full Text] [Related]
2. Tumor-promoting phorbol ester and ras oncogene expression inhibit the glucocorticoid-dependent transcription from the mouse mammary tumor virus long terminal repeat.
Vacca A; Screpanti I; Maroder M; Petrangeli E; Frati L; Gulino A
Mol Endocrinol; 1989 Oct; 3(10):1659-65. PubMed ID: 2558300
[TBL] [Abstract][Full Text] [Related]
3. Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3T3 cells transformed by ras oncogenes.
Sklar MD
Cancer Res; 1988 Feb; 48(4):793-7. PubMed ID: 3276398
[TBL] [Abstract][Full Text] [Related]
4. Cytoskeletal reorganization in NIH 3T3 fibroblasts expressing the ras oncogene.
Dartsch PC; Ritter M; Häussinger D; Lang F
Eur J Cell Biol; 1994 Apr; 63(2):316-25. PubMed ID: 8082656
[TBL] [Abstract][Full Text] [Related]
5. Human retinoblastoma gene product prevents c-Ha-ras oncogene mediated cellular transformation of mouse fibroblasts.
Kivinen L; Pitkänen K; Laiho M
Oncogene; 1993 Oct; 8(10):2703-11. PubMed ID: 8378082
[TBL] [Abstract][Full Text] [Related]
6. Transformation of rat ovarian epithelial and Rat-1 fibroblast cell lines by RAST24 does not influence cisplatin sensitivity.
Perez RP; Hamaguchi K; Tracey PA; Handel LM; Hamilton TC; Godwin AK
Cancer Res; 1993 Aug; 53(16):3771-5. PubMed ID: 8339290
[TBL] [Abstract][Full Text] [Related]
7. Resistance to apoptosis induced by alkylating agents in v-Ha-ras-transformed cells due to defect in p53 function.
Kuo ML; Chou YW; Chau YP; Huang TS
Mol Carcinog; 1997 Apr; 18(4):221-31. PubMed ID: 9142217
[TBL] [Abstract][Full Text] [Related]
8. Regulation of bradykinin B2 receptors by the ras oncogene: evidence for multiple mechanisms.
Hembree TN; Leeb-Lundberg LM
J Cell Physiol; 1996 Nov; 169(2):248-55. PubMed ID: 8908192
[TBL] [Abstract][Full Text] [Related]
9. Induction of p202, a modulator of apoptosis, during oncogenic transformation of NIH 3T3 cells by activated H-Ras (Q61L) contributes to cell survival.
Xin H; Geng Y; Pramanik R; Choubey D
J Cell Biochem; 2003 Jan; 88(1):191-204. PubMed ID: 12461788
[TBL] [Abstract][Full Text] [Related]
10. Selective activation of Ha-ras(val12) oncogene increases susceptibilityof NIH/3T3 cells to TNF-alpha.
Chang MY; Won SJ; Yang BC; Jan MS; Liu HS
Exp Cell Res; 1999 May; 248(2):589-98. PubMed ID: 10222151
[TBL] [Abstract][Full Text] [Related]
11. Enrichment for metallothionein does not confer resistance to cisplatin in transfected NIH/3T3 cells.
Morton KA; Jones BJ; Sohn MH; Datz FL; Lynch RE
J Pharmacol Exp Ther; 1993 Nov; 267(2):697-702. PubMed ID: 8246143
[TBL] [Abstract][Full Text] [Related]
12. Metastatic potential of cloned murine melanoma cells transfected with activated c-Ha-ras.
Price JE; Aukerman SL; Ananthaswamy HN; McIntyre BW; Schackert G; Schackert HK; Fidler IJ
Cancer Res; 1989 Aug; 49(15):4274-81. PubMed ID: 2663141
[TBL] [Abstract][Full Text] [Related]
13. A link between ras and metastatic behavior of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells.
Hofmann M; Rudy W; Günthert U; Zimmer SG; Zawadzki V; Zöller M; Lichtner RB; Herrlich P; Ponta H
Cancer Res; 1993 Apr; 53(7):1516-21. PubMed ID: 8453616
[TBL] [Abstract][Full Text] [Related]
14. Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice.
Gray GD; Hernandez OM; Hebel D; Root M; Pow-Sang JM; Wickstrom E
Cancer Res; 1993 Feb; 53(3):577-80. PubMed ID: 8425190
[TBL] [Abstract][Full Text] [Related]
15. Correlation of growth capacity of cells in hard agarose with successful transfection by the activated c-Ha-ras oncogene and in vivo proliferative capacity at metastatic sites.
Fidler IJ; Li LM; Ananthaswamy HN; Esumi N; Radinsky R; Price JE
Anticancer Res; 1991; 11(1):17-24. PubMed ID: 2018350
[TBL] [Abstract][Full Text] [Related]
16. Ha-rasVal12 oncogene increases susceptibility of NIH/3T3 cells to lovastatin.
Chang MY; Jan MS; Won SJ; Liu HS
Biochem Biophys Res Commun; 1998 Jul; 248(1):62-8. PubMed ID: 9675086
[TBL] [Abstract][Full Text] [Related]
17. Lack of influence of c-Ha-ras expression on the drug sensitivity of human bladder cancer histocultured in three-dimensions.
Theodorescu D; Connors KM; Groce A; Hoffman RM; Kerbel RS
Anticancer Res; 1993; 13(4):941-6. PubMed ID: 8352563
[TBL] [Abstract][Full Text] [Related]
18. Resistance to cytosine arabinoside in cells transfected with activated Ha-ras oncogene.
Riva C; el Khyari S; Rustum Y; Barra Y
Anticancer Res; 1995; 15(4):1297-302. PubMed ID: 7654012
[TBL] [Abstract][Full Text] [Related]
19. Enhanced lytic susceptibility of Ha-ras transformants after oncogene induction is specific to activated NK cells.
Johnson PW; Trimble WS; Hozumi N; Roder JC
J Immunol; 1987 Jun; 138(11):3996-4003. PubMed ID: 3495578
[TBL] [Abstract][Full Text] [Related]
20. Increased radiation resistance in transformed and nontransformed cells with elevated ras proto-oncogene expression.
Samid D; Miller AC; Rimoldi D; Gafner J; Clark EP
Radiat Res; 1991 May; 126(2):244-50. PubMed ID: 2023995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
